SOMERSET, N.J., Sept. 04, 2018 (GLOBE NEWSWIRE) -- MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, cloud-based healthcare IT and practice management solutions announced a strategic partnership with Salus Telehealth (“Salus”), a leading provider of telehealth solutions globally....
Tailwinds' Take: while not a huge client, this shows continued execution on the part of Catasys. Expect more of these client announcements going forward and strong guidance on the Q3 call in early November. Catasys, Inc. (CATS) (“Catasys” or the...
OLDWICK, N.J., Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In Lupus) study, a...
Tailwinds' Take: expecting more positive data out of Cchek. Big meeting with FDA in December will tell us how quickly this product can come to market. With positive results in two cancer indications with no alternative quality early stage...
GOLETA, CA - November 5, 2019 - Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, today announced financial results for the...
Tailwinds' Take: 5G is going to be a major factor for all wireless manufacturers. Can RESN carve out their niche in this space? The industry's reaction to XBAR at the upcoming MWC could be a good preliminary indicator. GOLETA, Calif.,...
Tailwinds' Take: PRVB finally ripped the bandaid off and raised this money. A couple key takeaways. The headline says $40 million, but the total was $60 with Amgen providing $20 million on the same terms. A very positive...
Tailwinds' Take: we are now positioned for the next acquisition. Expect that to be announced in the next few months. This remains one of our least expensive stocks on an EV to EBITDA basis and they are great buyers...
Tailwinds' Take: it appears that ITUS is seeing clinical success in multiple cancer types for them to be selecting a second indication at this early stage. This is a positive step in Cchek ultimately becoming a ubiquitous test for all...
Atomera is going to blow up. I mean this in a good way, not in the implosion sort of manner. ATOM is a ticking time bomb that is going to have a ballistic launch path sometime in the next...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.